Benjamin Landman is a child psychiatrist. He is chief resident at the Excellence Center for Autism and Neurodevelopmental Disorders at the Robert Debré Hospital, in Paris, France. He has a major interest in the identification of biomarkers in autism. He is mainly involved in the project SoNeTAA (Social Neuroscience for Therapeutic Approaches in Autism) and combines human-human and human-machine interactions with electroencephalography recording to study social cognition from a situated and reciprocal standpoint. The project aims to bridge the gap between state-of-the-art social neuroscience methods and clinical practices. He is also co-founder of the www.debrechildpsychiatry.org website.
Benjamin Landman
Chief resident
Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders
From this contributor
Coronavirus tool kit may aid families with autistic children during lockdown
To help families cope with the sudden loss of professional support during the pandemic, one team in France has created a set of resources and information.
Coronavirus tool kit may aid families with autistic children during lockdown
Explore more from The Transmitter
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.